$20.33
2.62% day before yesterday
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US03753U1060
Symbol
APLS

Apellis Pharmaceuticals, Inc. Stock price

$20.33
-2.82 12.18% 1M
+3.63 21.74% 6M
-11.58 36.29% YTD
-7.73 27.55% 1Y
-26.55 56.63% 3Y
-18.10 47.10% 5Y
+6.30 44.90% 10Y
+6.30 44.90% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+0.52 2.62%
ISIN
US03753U1060
Symbol
APLS
Industry

New AI Insights on Apellis Pharmaceuticals, Inc. Insights AI Insights on Apellis Pharmaceuticals, Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$2.5b
Net debt
positive
Cash
$479.2m
Shares outstanding
126.5m
Valuation (TTM | estimate)
P/E
59.8 | negative
P/S
2.5 | 2.6
EV/Sales
2.5 | 2.6
EV/FCF
32.4
P/B
6.4
Financial Health
Equity Ratio
25.8%
Return on Equity
-86.6%
ROCE
10.3%
ROIC
-
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$1.0b | $979.8m
EBITDA
$82.1m | $109.7m
EBIT
$80.4m | $-34.4m
Net Income
$45.0m | $-3.1m
Free Cash Flow
$78.6m
Growth (TTM | estimate)
Revenue
42.1% | 25.4%
EBITDA
137.1% | 167.2%
EBIT
136.0% | 79.2%
Net Income
118.0% | 98.4%
Free Cash Flow
138.3%
Margin (TTM | estimate)
Gross
88.9%
EBITDA
8.1% | 11.2%
EBIT
7.9%
Net
4.4% | -0.3%
Free Cash Flow
7.7%
More
EPS
$0.3
FCF per Share
$0.6
Short interest
15.8%
Employees
708
Rev per Employee
$1.1m
Show more

Is Apellis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Apellis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:

19x Buy
70%
7x Hold
26%
1x Sell
4%

Analyst Opinions

27 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:

Buy
70%
Hold
26%
Sell
4%

Financial data from Apellis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,016 1,016
42% 42%
100%
- Direct Costs 113 113
17% 17%
11%
903 903
46% 46%
89%
- Selling and Administrative Expenses 525 525
1% 1%
52%
- Research and Development Expense 298 298
7% 7%
29%
82 82
137% 137%
8%
- Depreciation and Amortization 1.68 1.68
8% 8%
0%
EBIT (Operating Income) EBIT 80 80
136% 136%
8%
Net Profit 45 45
118% 118%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Apellis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apellis Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
Apellis Pharmaceuticals, Inc. ( APLS ) Stifel 2025 Healthcare Conference November 12, 2025 2:40 PM EST Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Executive Vice President of Commercial Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Annabel Samimy Stifel, Nicolaus & Company, Incorporated, Researc...
Neutral
GlobeNewsWire
4 days ago
WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the leading treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Neutral
GlobeNewsWire
11 days ago
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET.
More Apellis Pharmaceuticals, Inc. News

Company Profile

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Head office United States
CEO Cedric Francois
Employees 708
Founded 2009
Website apellis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today